BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Hypnion, Inc. Raises $20.1M In Extended Series B Financing


12/19/2005 10:23:37 AM

LEXINGTON, Mass., Dec. 19 /PRNewswire/ -- Hypnion, Inc., today announced that it raised $20.1 million in an extension of its Series B private equity financing, in response to favorable clinical results in its lead insomnia program. Investors included MPM Capital, Advanced Technology Ventures, Forward Ventures, Flagship Ventures, Oxford Bioscience Partners, GIMV, S.R. One Limited, JAFCO, Alexandria Real Estate Equities, and Mintz Levin Investments. With this financing, Hypnion expects to rapidly advance its lead program into Phase II and a second compound into Phase I.

"This financing demonstrates the confidence and excitement of our investors in the promise and market potential of our clinical programs," said John F. Dee, President and Chief Executive Officer.

Hypnion has discovered and is developing a unique and proprietary series of highly selective H1 receptor modulators to treat chronic insomnia. The basis for these discoveries stemmed from the company's Research and Development efforts that heavily employed SCORE-2004(TM), a proprietary pharmacological drug discovery system for the selection of clinical candidates in insomnia and other neurobiological indications. Pre-clinical studies have demonstrated that Hypnion's proprietary compounds have superior efficacy and side-effect profiles than the leading marketed drugs including Ambien, Lunesta, doxepin, and trazodone. Given their mechanism of action, Hypnion's compounds may have the opportunity to be classified as non-scheduled medications, unlike Ambien and Lunesta. Hypnion believes they could represent a major improvement in the treatment of insomnia. The Company has filed for a broad and comprehensive patent estate for composition of matter and method of use patents.

Insomnia is a serious condition that affects a large number of patients. According to the National Sleep Foundation's Sleep in America Poll 2005, approximately 50% of the adult population reported experiencing at least one symptom of insomnia for several nights a week during the last year. Sleep loss is known to impact learning and memory, and recent research indicates that sleep deprivation not only depresses the immune system, but also may make us vulnerable to many other diseases. To put it into context, the prevalence of insomnia is larger than that of anxiety or depression.

About Hypnion

Hypnion is a neuroscience drug discovery and development company focused on sleep disorders. Our product candidates and research capabilities address large untapped markets including insomnia, excessive daytime sleepiness, sleep apnea, restless legs syndrome, and fibromyalgia. The Company was founded by prominent and highly regarded scientists in the field of sleep disorder research and has proprietary rights to the worlds' most advanced sleep-wake drug discovery system, SCORE-2004(TM). The system is highly predictive of human response and allows high-throughput testing of drug candidates at the pre-clinical stage to optimize the next generation of safe, non-addictive therapies for this vast and untreated market.

Contacts: John F. Dee Michael E. Fitzgerald President and CEO Chief Financial Officer Hypnion, Inc. Hypnion, Inc. (781) 778-0212 (781) 778-0216 jdee@hypnion.com mfitzgerald@hypnion.com

Source: Hypnion, Inc.



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES